Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding lab results in another language, especially when Sera Prognostics’ disclosures span clinical-trial endpoints, cash-burn tables and biomarker patents. If you have ever wondered how to track Sera Prognostics insider trading Form 4 transactions before pivotal data releases or needed to locate R&D spend buried deep in the notes, you know the challenge.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn a 300-page 10-K into a two-minute brief, flagging exactly where the company discusses pre-term birth biomarkers, partnership milestones and patent litigation risks. Real-time alerts surface every filing type the moment it hits EDGAR, including:
- Sera Prognostics quarterly earnings report 10-Q filing with segment growth and burn-rate trends
- Sera Prognostics annual report 10-K simplified for long-term obligations and IP strategy
- Sera Prognostics proxy statement executive compensation to benchmark leadership incentives
- Sera Prognostics 8-K material events explained for clinical-trial results or financing updates
- Sera Prognostics Form 4 insider transactions real-time so you never miss an executive stock move
Whether you’re analysing cash runway, comparing quarter-over-quarter biomarker adoption, or simply understanding Sera Prognostics SEC documents with AI, Stock Titan streamlines your workflow. Use the Sera Prognostics earnings report filing analysis to assess revenue from diagnostic sales, or dive into Sera Prognostics executive stock transactions Form 4 for sentiment signals. Complex biotech disclosures are now clear, timely and actionable—no scientific background required.
Sera Prognostics Chief Commercial Officer Dyaarl Lee Anderson Jr. received significant equity compensation on June 23, 2025, consisting of two components:
- 67,114 Restricted Stock Units (RSUs) with a four-year vesting schedule: - 25% vests on June 10, 2026 - Remaining 75% vests quarterly over three years
- 102,534 Stock Options with strike price of $1.87: - 25% vests on June 10, 2026 - Remaining 75% vests monthly over three years
Both grants require continued service with the company. The equity awards suggest a long-term retention strategy for the Chief Commercial Officer position, with zero-cost RSUs balanced against performance-based stock options. The relatively low strike price of $1.87 indicates potential upside opportunity in the company's growth prospects.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
What is the primary focus of Sera Prognostics, Inc.?
How do Sera Prognostics' tests benefit healthcare providers?
What technology underpins Sera Prognostics' diagnostic tests?
How does Sera Prognostics differentiate itself in the diagnostic testing market?
Can you explain the significance of biomarker testing in maternal care?
What role do partnerships play in the company’s strategy?
What is the importance of clinical evidence for Sera Prognostics?
How is Sera Prognostics positioned within the broader maternal health diagnostic landscape?
